Albireo
Clinical trials sponsored by Albireo, explained in plain language.
-
New drug trial targets silent liver disease
Disease control CompletedThis study tested whether a drug called elobixibat could help adults with fatty liver disease (NAFLD or NASH). Forty-seven participants were randomly assigned to receive either the drug or a placebo for 16 weeks. Researchers measured changes in liver fat, cholesterol levels, and …
Phase: PHASE2 • Sponsor: Albireo • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Hope for kids with rare liver disease: new drug targets debilitating itching and liver damage
Disease control CompletedThis study tested whether a drug called A4250 could help children with rare, progressive liver diseases known as PFIC1 and PFIC2. The main goals were to see if the drug could lower harmful bile acids in the blood and reduce the severe, life-altering itching these children experie…
Phase: PHASE3 • Sponsor: Albireo • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC